Background: A new autoantibody (termed NMO-IgG, or AQP4-Ab) has recently been described in patients with neuromyelitis optica (NMO) and its formes frustes, longitudinally extensive transverse myelitis (LETM) and recurrent optic neuritis (rON). However, AQP4-Ab has been found also in patients with co-existing rheumatic diseases such as systemic lupus erythematosus (SLE) or Sjögren’s syndrome (SS), conditions which are characterized by broad, polyspecific B cell activation.
Objectives: In this study, we aimed at evaluating the syndrome specificity and frequency of AQP4-Ab in patients with rheumatic diseases and neurological symptoms.
Methods: For this purpose, serum samples from 109 neurological patients with established connective tissue disorders (CTD) (n = 54), possible CTD (n = 42), or vasculitis (n = 13) were analysed for the presence of AQP4-Ab by a cell-based assay employing recombinant human AQP4.
Results: AQP4-Ab was detectable in 31/40 (78%) patients with CTD and NMO spectrum disorders (median titre, 1:1000) but in none of the samples obtained from patients with CTD or vasculitis and neurological disorders other than NMO, LETM, or rON (n = 69).
Conclusion: The high syndrome specificity of the antibody for neuromyelitis optica spectrum disorders (NMOSDs) in patients with CTD supports the concept of AQP4-Ab being involved in the pathogenesis of these neurological conditions, and argues against AQP4-Ab simply being part of the polyclonal B cell activation generally associated with rheumatic diseases. Moreover, the finding that AQP4-Ab is present in patients with CTD and co-existing NMOSD with approximately the same frequency as in patients without CTD strengthens the case of CTD and AQP4-Ab positive NMOSD representing two co-existing yet distinct entities in the majority of patients.
WingerchukDMLennonVAPittockSJLucchinettiCFWeinshenkerBG. Revised diagnostic criteria for neuromyelitis optica. Neurology2006; 66: 1485–1489.
2.
WeinshenkerBGWingerchukDMVukusicS. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol2006; 59: 566–569.
3.
MatielloMLennonVAJacobA. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology2008; 70: 2197–2200.
4.
Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298(1–2): 158–162.
5.
LennonVAWingerchukDMKryzerTJ. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet2004; 364: 2106–2112.
6.
JariusSFranciottaDBergamaschiR. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology2007; 68: 1076–1077.
7.
LennonVAKryzerTJPittockSJVerkmanASHinsonSR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med2005; 202: 473–477.
8.
PaulFJariusSAktasO. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med2007; 4: e133–e133.
9.
PittockSJLennonVAde SezeJ. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol2008; 65: 78–83.
10.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
11.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
12.
VitaliCBombardieriSJonssonR. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis2002; 61: 554–558.
13.
MasiATRodnanGPMedsgerTAAltmanRD. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum1980; 23: 581–590.
14.
MoorePMRichardsonB. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiatry1998; 65: 10–22.
15.
CalabreseLHMallekJA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore)1988; 67: 20–39.
16.
JariusSProbstCBorowskiK. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci2010; 291: 52–56.
17.
WandingerKPStangelMWitteT. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum2010; 62: 1198–1200.
18.
JariusSPaulFFranciottaD. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol2008; 4: 202–214.
19.
JariusSWildemannB. AQP4 antibodies in neuromyelitis optica: pathogenic and diagnostic relevance. Nature Rev Neurol2010; 6: 383–392.
20.
WingerchukDMHogancampWFO’BrienPCWeinshenkerBG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology1999; 53: 1107–1114.
21.
CreeBALambSMorganKChenAWaubantEGenainC. An open label study of the effects of rituximab in neuromyelitis optica. Neurology2005; 64: 1270–1272.
22.
JacobAWeinshenkerBGViolichI. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol2008; 65: 1443–1448.
23.
MandlerRNAhmedWDencoffJE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology1998; 51: 1219–1220.
24.
KeeganMPinedaAAMcClellandRLDarbyCHRodriguezMWeinshenkerBG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology2002; 58: 143–146.
25.
NakashimaITakahashiTNishiyamaS. Plasma exchange for neuromyelitis optica with aquaporin-4 antibody. Neurology2009; 72: A187–A187.
26.
KayCSScolaRHLorenzoniPJJariusSArrudaWOWerneckLC. NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci2008; 275: 148–150.
27.
McKeonALennonVAJacobA. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve2009; 39: 87–90.
28.
BergamaschiRJariusSRobottiMPichiecchioAWildemannBMeolaG. Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol2009.
29.
JacobSZareiMKentonAAllroggenH. Gluten sensitivity and neuromyelitis optica: two case reports. J Neurol Neurosurg Psychiatry2005; 76: 1028–1030.
30.
JariusSJacobSWatersPJacobALittletonEVincentA. Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatry2008; 79: 1084–1084.
31.
BradlMMisuTTakahashiT. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol2009; 66: 630–643.
32.
BennettJLLamCKalluriSR. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol2009; 66: 617–629.
33.
SaadounSWatersPBellBAVincentAVerkmanASPapadopoulosMC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain2010; 133: 349–361.
34.
HinsonSRPittockSJLucchinettiCF. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology2007; 69: 2221–2231.
35.
WatersPJariusSLittletonE. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Archives of neurology2008; 65: 913–919.
36.
VincentTSaikaliPCayrolR. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood–brain barrier permeability and granulocyte recruitment. J Immunol2008; 181: 5730–5737.
37.
SaadounSWatersPBellBAVincentAVerkmanASPapadopoulosMC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain2010; 133: 349–361.
38.
KinoshitaMNakatsujiYKimuraT. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun2010.
39.
JariusSAboul-EneinFWatersP. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain2008; 131: 3072–3080.
40.
NishiyamaSItoTMisuT. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology2009; 72: 1960–1961.
41.
JariusSPaulFMartins da SilvaA. Neuromyelitis optica and longitudinally extensive transverse myelitis following thymectomy for myasthenia gravis. Mult Scler2007; 13: P534–P534.
42.
KinoshitaMNakatsujiYKimuraT. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun2009; 386: 623–627.
43.
CerveraRKhamashtaMAHughesGR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus2009; 18: 869–874.
44.
BonnanMValentinoROlindoSMehdaouiHSmadjaDCabreP. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler2009; 15: 487–492.
45.
TakahashiTFujiharaKNakashimaI. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain2007; 130: 1235–1243.
46.
MatsushitaTIsobeNMatsuokaT. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler2009; 15: 834–847.
47.
ChanKHKwanJSHoPWHoJWChuACRamsdenDB. Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation2010; 7: 50–50.
48.
MaderSLutterottiADi PauliF. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One2010; 5: e10455–e10455.
